01. Key Dates

• Abstract Submission Deadline: February 1^st (Sun.) 23:59 KST, 2026
• Notification of Acceptance: In Mid of March, 2026

03. Abstract Format

Abstracts should be submitted online in English.

The abstract structure should be as follows:
- Abstract should be structured into the following headings: Background, Methods, Result, and Conclusion.
- Abstract should not exceed 300 words. (Excluding Abstract Title and Spaces)

The maximum number of authors is 30 per abstract.

You may include one (1) figure or table in your abstract.

If an author is affiliated with hospital as well as university, please enter the name of the hospital for which he/she works.

04. GBCC Academic Award (Best, Excellence, Honorable Mention)

Authors of the top 8 submitted abstract will be assigned to the General Session to present on-site.

The awardees will be determined through on-site evaluation conducted during the General Session I, II.

Please refer to the GBCC Academic Award page for more detailed information.

05. Conflicts of Interest

The conflict of interest policy requirements applies to all abstract authors. Any potential conflict of interest must be indicated upon abstract submission.
It is the responsibility of the Presenting Author to obtain disclosure information from all co-authors and to provide disclosure of all interests and relationships. This includes any financial or other relationships with commercial entities whose products or services are related to the subject matter in the manuscript, or sociopolitical issues that can cause conflict.

06. Encore Abstract Submission

Eligibility for Encore Abstracts

Encore abstracts may be submitted if the work has been previously presented only in abstract form, including poster or oral presentations at other scientific meetings.

Abstracts that have been published as a full-length manuscript in a peer-reviewed journal prior to GBCC submission are not eligible.

Acceptable Updated Data for Encore Abstracts

To maintain scientific clarity while allowing meaningful updates, GBCC permits limited updated data within the ranges commonly accepted by major international oncology congresses.
• Updated Enrollment Numbers:
    Increased sample size is allowed if it remains within 10-20% of the originally presented cohort.
    (Examples: N=100 → 110-120; N=200 → 220-240)
• Updated Follow-up Duration:
    Additional follow-up of approximately +3 to +6 months in median follow-up time is permitted.
• Limited Subgroup Data:
    Up to 1-2 small, descriptive subgroup analyses may be added, provided that they simply support or refine the original findings.
    (Examples: age-based groups, HR/HER2 subgroups, stage-based comparisons)

Updates Not Permitted

The following additions exceed the scope of an encore abstract and therefore render the submission ineligible:
• Introduction of new primary or secondary endpoints
• Addition of major new datasets (e.g., biomarker, genomic, imaging analyses)
• Inclusion of exploratory or extensive subgroup analyses
• Substantial analytical modifications or a new statistical analysis plan
• Addition of a new patient cohort, study arm, or multi-institutional expansion
• Any update that fundamentally alters the study findings
• Such submissions should be prepared as a new abstract, not an encore abstract.

Purpose and Rationale

The GBCC Encore Abstract Policy aligns with global oncology congress standards to:
• Provide a platform for broader dissemination of important scientific findings
• Avoid unnecessary duplication or redundancy
• Maintain consistency with ethical publication practices
• Ensure clarity and integrity in scientific communication

Encore abstracts allow previously presented research to reach a new and international audience, while maintaining respect for
originality and scientific rigor.

Compliance Review

All encore abstract submissions will be reviewed by the GBCC Abstract Review Committee to determine compliance with the above criteria.

Abstracts exceeding acceptable update limits may be reclassified or rejected at the committee’s discretion.

07. Acceptance Notification

Abstract acceptance will be notified by e-mail.

The decision of the Scientific Committee regarding abstract acceptance is final. While authors’ presentation preferences will be taken into consideration, the Committee may assign an alternative format if deemed appropriate. Please note that the decision cannot be appealed.

The first author or corresponding author should reply to the notification of acceptance of their abstract for attendance confirmation.

08. Abstract Modification or Withdrawal

You can modify or withdraw your abstract on the submission online page within deadline.

The request for modification or withdrawal after the abstract submission deadline must be submitted through email (gbccabs@intercom.co.kr).

The first author or corresponding author may request a correction of error (e.g., typos, misspellings, grammatical errors).

If the presenting author does not register for GBCC 2026 by the registration deadline, his/her abstract will be automatically withdrawn.